Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
17 authors.
Cecilia P SanchezCenter for Infectious Diseases, Parasitology, University Hospital Heidelberg, Medical Faculty, Heidelberg University, Heidelberg, Germany.
Maëlle DuffeyCenter for Infectious Diseases, Parasitology, University Hospital Heidelberg, Medical Faculty, Heidelberg University, Heidelberg, Germany.ORCID 0000-0002-4319-0647
Romina V CeladaCenter for Infectious Diseases, Parasitology, University Hospital Heidelberg, Medical Faculty, Heidelberg University, Heidelberg, Germany.
Michal KucharskiSchool of Biological Sciences, Nanyang Technological University, Singapore, Singapore.ORCID 0000-0002-1505-5608
Marie HoarauNational Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency, Thailand Science Park, Khlong Luang, Pathum Thani, Thailand.ORCID 0000-0002-5758-3556
Thanaya SaeyangNational Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency, Thailand Science Park, Khlong Luang, Pathum Thani, Thailand.
Sumalee KamchonwongpaisanNational Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency, Thailand Science Park, Khlong Luang, Pathum Thani, Thailand.
Farzin SohrabyInstitute of Chemistry, Technische Universität Berlin, Berlin, Germany.
Svenja de BuhrCenter for Infectious Diseases, Parasitology, University Hospital Heidelberg, Medical Faculty, Heidelberg University, Heidelberg, Germany.ORCID 0000-0002-5368-3816
Ariane Nunes AlvesInstitute of Chemistry, Technische Universität Berlin, Berlin, Germany.ORCID 0000-0002-5488-4732
Amuza Byaruhanga LuckyDivision of Infectious Diseases and International Medicine, Department of Internal Medicine Morsani College of Medicine, University of South Florida, Tampa, FL, USA.ORCID 0000-0001-6779-1888
Jun MiaoDivision of Infectious Diseases and International Medicine, Department of Internal Medicine Morsani College of Medicine, University of South Florida, Tampa, FL, USA.ORCID 0000-0001-9374-6749
Clement RegnaultGlasgow Shared Research Facility, College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, UK.
Jerzy M DziekanSchool of Biological Sciences, Nanyang Technological University, Singapore, Singapore.ORCID 0000-0002-5277-0395
Michael P BarrettSchool of Infection & Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.ORCID 0000-0001-9447-3519
Michael LanzerCenter for Infectious Diseases, Parasitology, University Hospital Heidelberg, Medical Faculty, Heidelberg University, Heidelberg, Germany. Michael.Lanzer@med.uni-heidelberg.de.ORCID 0000-0002-0220-6526
Funding
Bundesministerium für Bildung, Wissenschaft, Forschung und Technologie (Federal Ministry for Education, Science, Research and Technology) DZIF; project TTU 03.803
6 · The paper itself
Abstract
The emergence of multi-drug resistant Plasmodium falciparum underscores the urgent need for new antimalarial therapies. SC83288, a chemically distinct antimalarial compound, is highly effective against P. falciparum both in vivo and in vitro, including strains resistant to artemisinin and partner drugs. Here, we show that SC83288 disrupts blood-stage development by blocking DNA replication and arresting karyokinesis. We identify the parasite's DNA and tRNA
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Mechanisms of PfDNMT2 inhibition and PfATP6-mediated resistance to the antimalarial candidate SC83288 in Plasmodium falciparum. · full record | OpenQuestion